Telix Joins Thera4Care for Phase 1 Trial of Terbium-161 FAP-Targeting Cancer Therapy

• Telix Pharmaceuticals joined Thera4Care to evaluate a terbium-161 version of its FAP-targeting therapy candidate in a Phase 1 clinical trial.
• The study will assess safety and preliminary activity in metastatic solid tumors, initially focusing on ovarian cancer, pancreatic cancer and sarcomas.
• Results are expected from future research to inform development of TLX400-Tx, which uses lutetium-177.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN89447) on November 05, 2026, and is solely responsible for the information contained therein.